KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Receivables - Net: 2009-2024

Historic Receivables - Net for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $6.2 billion.

  • Regeneron Pharmaceuticals' Receivables - Net fell 6.88% to $5.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 billion, marking a year-over-year decrease of 6.88%. This contributed to the annual value of $6.2 billion for FY2024, which is 9.61% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Receivables - Net of $6.2 billion as of FY2024, which was up 9.61% from $5.7 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Receivables - Net ranged from a high of $6.2 billion in FY2024 and a low of $4.1 billion during FY2020.
  • Its 3-year average for Receivables - Net is $5.7 billion, with a median of $5.7 billion in 2023.
  • In the last 5 years, Regeneron Pharmaceuticals' Receivables - Net surged by 95.94% in 2020 and then declined by 11.73% in 2022.
  • Regeneron Pharmaceuticals' Receivables - Net (Yearly) stood at $4.1 billion in 2020, then soared by 46.71% to $6.0 billion in 2021, then declined by 11.73% to $5.3 billion in 2022, then grew by 6.35% to $5.7 billion in 2023, then increased by 9.61% to $6.2 billion in 2024.